OneSource Specialty Pharma Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/q0j9qiub8g5ki42ylrke0zk4.pdf

Key Takeaways


The Revenue Trough: Why Q3 Was Soft

Neeraj Sharma: "what is really heartening for us, and it should be also for our investors, is that the underlying demand of our business remains absolutely robust."

The Commercial Ramp: Approvals, Markets & Timing


The FY28 Bridge: How Management Plans to Get There

Arun Kumar: "We remain extremely confident on our ability to achieve these targets, and I will explain why we believe so."

Biologics: The Optionality That Is Becoming Real

Neeraj Sharma: "we are most excited about our nascent biologics business, which has benefited from some very strong tailwinds, both from the new FDA guidelines on biosimilars, as well as the passage of the Biosecure Act in the U.S."

Partnership Philosophy & Contract Discipline

Neeraj Sharma: "What we gain from being acting like partners and not like mercenary CDMOs is to really gain a long term partnership with the customers..."

Other Businesses & Operational Updates


Guidance & Commitments

CommitmentSpecificsTimeline
FY28 revenue & EBITDA$400 mn revenue, $160 mn EBITDA, organicallyFY28
Exit run rate as proxyQ4 FY27 exit run rate to closely approximate FY28 guidanceQ4 FY27
Canadian approvalBased on partner guidance, approval expectedBetween now and May
Emerging market COPPCertificate expected, triggering flurry of partner approvalsFirst few days of April
Capacity expansionAlmost 20 crore installed capacity availableBy end of FY27
Net debt ceilingLess than 1.5x of EBITDANear-term
Base business debt-freeOn ₹50 cr / ₹20 cr EBITDA base businessBy FY28
Acquisition closeFinal regulatory approvals for two injectable facilitiesQ3 FY27
Oncology launchBranded NDA product with one competitorNext quarter

Key Metrics

MetricQ3 FY26
Revenue₹290.3 cr, 26% YoY decline and down ~US$10 mn QoQ
EBITDA₹17.3 cr, declined by roughly the same amount as the revenue shortfall QoQ
Adjusted PAT (loss)₹(47.2) cr
Adjusted diluted EPS₹(4.1) per share
FY28 revenue guidance$400 mn, reiterated, organic, excludes inorganic accretions
FY28 EBITDA guidance$160 mn, reiterated
Capex planOver ₹700 cr to increase capacities, progressing well
Capex committed~75% of total planned ₹10 cr capex investment spend for flagship site
Customer advances~₹250 cr held as advances from customers pre-booking capacities
Workforce addition~300 new FTEs added year-to-date at flagship site, doubling workforce
Biologics RFP growth~4x versus end of last year
Effective interest rateBelow 9%, 200 bps lower versus last year
Net debt-to-EBITDA guidanceBelow 1.5x, near-term peak guidance
Regulatory and customer inspections36 year-to-date
DDC base capacity utilization (peak)70–75% typical for sterile injectables at full commercial scale